Serum Ferritin During the Course of Chronic Myeloid Leukemia. Increase of Serum Ferritin as a Marker of Dyserythropoiesis

Publisher Website
Google Scholar
Abstract
A solid-phase immunoradiometric assay for serum ferritin was developed and applied to 30 patients with chronic myeloid leukemia (CML), including 13 patients with a typical chronic phase, 12 with bone marrow fibrosis without evidence of an acute phase and 5 with an acute phase. Patients were divided into 3 subgroups according to the erythrokinetic data as studied by the 59Fe kinetic test. Serum ferritin was clearly correlated with the quality of erythropoiesis but not with blast cell mass nor white cell count. Given the prognostic value of dyserythropoiesis in the course of CML, serum ferritin determination may be a helpful and simple parameter in the follow-up of CML patients.